

## AXIRON NET SALES, QUARTER TO 31 MARCH 2013

Acrux (ASX: ACR) today confirmed that Eli Lilly reported Axiron net sales of \$37.1 million in its financial results for the quarter ended 31 March 2013. Net sales reported by Lilly for the previous quarter to 31 December 2012 were \$23.9 million.

### Contact

Jon Pilcher, CFO: 0438 422 271

### About Acrux

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- Fast-drying, invisible sprays or liquids provide a delivery platform with low or no skin irritation, superior cosmetic acceptability and simple, accurate and flexible dosing. The technology platform is covered by broad and well-differentiated, issued patents.
- Acrux has products marketed by licensees in the United States, approved in Europe, Canada and Australia and in registration or development.